Sarepta Therapeutics Inc. has obtained expanded US approval for its gene therapy to treat more children with a fatal muscle disease, despite lacking clear evidence of its benefits in clinical trials.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing